Published in Qual Life Res on March 24, 2017
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Modeling valuations for EuroQol health states. Med Care (1997) 21.66
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Measurement of health state utilities for economic appraisal. J Health Econ (1986) 11.70
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73
The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med (2001) 5.89
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis (2010) 4.28
The time trade-off method: results from a general population study. Health Econ (1996) 4.17
The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol (2005) 3.56
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis (2009) 3.32
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis (2005) 2.92
Antiretroviral therapy and management of HIV infection. Lancet (2010) 2.84
The evolving epidemiology of HIV/AIDS. AIDS (2012) 2.41
Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS (2014) 2.26
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med (2010) 2.17
A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making (2002) 2.12
Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS (2011) 2.11
Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making (2002) 1.94
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS (2012) 1.90
Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr (2011) 1.71
No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr (2012) 1.63
Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr (2008) 1.62
Renal safety of tenofovir disoproxil fumarate. AIDS Read (2007) 1.58
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther (2007) 1.55
Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value Health (2008) 1.55
A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLoS Med (2012) 1.47
Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med (2009) 1.42
Are QALYs based on time trade-off comparable?--A systematic review of TTO methodologies. Health Econ (2005) 1.41
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis (2011) 1.32
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS (2011) 1.28
The effect of diagnosis with HIV infection on health-related quality of Life. Qual Life Res (2006) 1.18
A programme of symptom management for improving quality of life and drug adherence in AIDS/HIV patients. J Adv Nurs (2006) 1.07
Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials (2004) 1.07
A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health (2008) 1.04
Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr (2005) 1.01
The symptom experience of people living with HIV and AIDS in the Eastern Cape, South Africa. BMC Health Serv Res (2008) 0.99
It's all in the name, or is it? The impact of labeling on health state values. Med Decis Making (2011) 0.97
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). JACC Heart Fail (2014) 0.94
Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Med Care (1995) 0.92
Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Qual Life Res (1997) 0.90
Longitudinal and cross sectional assessments of health utility in adults with HIV/AIDS: a systematic review and meta-analysis. BMC Health Serv Res (2015) 0.89
Utilities derived from visual analog scale scores in patients with HIV/AIDS. Med Decis Making (2003) 0.87
Economic methods for measuring the quality of life associated with HIV infection. Qual Life Res (1999) 0.86
Utility assessment of HIV/AIDS-related health states in HIV-infected Ugandans. AIDS (2008) 0.84
Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study. Res Social Adm Pharm (2011) 0.84
Health utilities in patients with HIV/AIDS in Thailand. Value Health (2010) 0.83
Health state utilities for skeletal-related events secondary to bone metastases. Eur J Health Econ (2013) 0.82
Acute and chronic impact of cardiovascular events on health state utilities. BMC Health Serv Res (2015) 0.80
A systematic literature review of cardiovascular event utilities. Expert Rev Pharmacoecon Outcomes Res (2013) 0.79
Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Relat Outcome Meas (2015) 0.77
Art therapy for relief of symptoms associated with HIV/AIDS. AIDS Care (2009) 0.77
Health state utilities associated with attributes of treatments for hepatitis C. Eur J Health Econ (2014) 0.77
Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. Health Qual Life Outcomes (2015) 0.75
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. Lancet HIV (2015) 1.40
Health state utilities associated with attributes of treatments for hepatitis C. Eur J Health Econ (2014) 0.77
A qualitative examination of the content validity of the EQ-5D-5L in patients with type 2 diabetes. Health Qual Life Outcomes (2015) 0.77
The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation. Eur J Health Econ (2015) 0.75
Health State Utilities Associated with Glucose Monitoring Devices. Value Health (2016) 0.75
Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Serv Res (2017) 0.75